AUC(0-t)
Showing 1 - 25 of >10,000
Breast Cancer Trial (Trastuzumab Deruxtecan)
Not yet recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
- (no location specified)
Jul 10, 2023
Lymphoma Trial in Seattle (biological, other, procedure)
Not yet recruiting
- Lymphoma
- Immune Globulin Infusion (Human), 10% Solution
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 21, 2023
Upper Abdomen Imaging With Low Field MRI Scanner (0.4T)
Not yet recruiting
- Abdominal Pain
- Diagnostic MRI
- (no location specified)
Sep 15, 2023
Triple Negative Breast Cancer Trial in Guangzhou (Gemcitabine and carboplatin plus antibiotic (moxifloxacin), Gemcitabine
Recruiting
- Triple Negative Breast Cancer
- Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
- Gemcitabine combined with carboplatin plus placebo
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 6, 2022
Aphakia Trial in United States (Clareon Vivity/Vivity Toric Extended Vision IOL, Clareon/Clareon Toric Aspheric IOL)
Not yet recruiting
- Aphakia
- Clareon Vivity/Vivity Toric Extended Vision IOL
- Clareon/Clareon Toric Aspheric IOL
-
Torrance, California
- +6 more
May 2, 2023
EBV-positive Nasopharyngeal Carcinoma Trial in Guangzhou (Cohort A: 3.0x10^6 CAR-T cells/kg, Cohort B: 9.0x10^6CAR-T cells/kg,
Not yet recruiting
- EBV-positive Nasopharyngeal Carcinoma
- Cohort A: 3.0x10^6 CAR-T cells/kg
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 16, 2023
Bradycardia, Tachycardia, Heart Failure Trial (China market released 3.0T Magnetic resonance (MR) conditional CIED systems)
Not yet recruiting
- Bradycardia
- +2 more
- China market released 3.0T Magnetic resonance (MR) conditional CIED systems
- (no location specified)
Sep 12, 2023
Spondyloarthropathy, Tendinopathy Trial in Bordeaux (MRI ZTE2 sequence)
Recruiting
- Spondyloarthropathy
- Tendinopathy
- MRI ZTE2 sequence
-
Bordeaux, FranceCHU de Bordeaux
Dec 26, 2022
Clareon IOL Retrospective Data Collection
Not yet recruiting
- Aphakia
- Astigmatism
- Clareon UVA IOL
- +2 more
-
Fort Worth, TexasAlcon Research, LLC
Mar 22, 2023
Multiple Myeloma Trial (BCMA-TGFß CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFß CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFß CAR-T
Not yet recruiting
- Multiple Myeloma
- BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
- +3 more
- (no location specified)
Jul 28, 2023
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy, distant lymph node 0.5Gy*4)
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Dec 6, 2022
Vancomycin, Adult, Area Under Curve Trial in Greenfield Park (Vancomycin dose adjustment using the Bayesian method, Vancomycin
Completed
- Vancomycin
- +2 more
- Vancomycin dose adjustment using the Bayesian method
- Vancomycin dose adjustment using the trough level method
-
Greenfield Park, Quebec, CanadaCharles-Le Moyne Hospital
Sep 9, 2021
Breast Cancer Trial in Detroit (biological, drug, other)
Terminated
- Breast Cancer
- HER2Bi-armed activated T cells
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Nov 29, 2022
Healthy Volunteers Trial in Newark (Bimatoprost Ophthalmic)
Not yet recruiting
- Healthy Volunteers
- Bimatoprost Ophthalmic
-
Newark, New JerseyBiotrial
Feb 6, 2023
Stereotactic Margins in Localized Bronchial Cancer (T1/T2a, N0)
Recruiting
- Bronchial Cancer
-
Strasbourg, FranceService de chirurgie thoracique - CHU de Strasbourg - France
Oct 28, 2022
Bioequivalence Trial in Chennai (Eszopiclone 3mg Test Drug T-1 Coated Tablets, Eszopiclone 3mg Test Drug T-2 Coated Tablets,
Completed
- Bioequivalence
- Eszopiclone 3mg Test Drug T-1 Coated Tablets
- +2 more
-
Chennai, Tamil Nadu, IndiaAzidus Laboratories Ltd.
Apr 22, 2022
Colonic Tumors Trial (Dostarlimab, CAPEOX, FOLFOX)
Not yet recruiting
- Colonic Neoplasms
- Dostarlimab
- +2 more
- (no location specified)
May 3, 2023
CAR T-Cell Therapy Trial in Shenzhen (HEC-016(0.5×10^6 CAR-T Cells), HEC-016(0.5×10^6.5 CAR-T Cells), HEC-016(0.5×10^7 CAR-T
Recruiting
- CAR T-Cell Therapy
- HEC-016(0.5×10^6 CAR-T Cells)
- +2 more
-
Shenzhen, Guangdong, ChinaShenzhen Luohu Hospital
Mar 3, 2022
Pressure Injury, Venous Leg Ulcer, Pressure Injury Stage 2 Trial in Calgary, Edmonton (NanoSALV Catalytic)
Recruiting
- Pressure Injury
- +6 more
- NanoSALV Catalytic
-
Calgary, Alberta, Canada
- +3 more
Jan 31, 2023
Oral Squamous Cell Carcinoma, Neck Dissection Trial (Elective neck dissection, Therapeutic neck dissection)
Not yet recruiting
- Oral Squamous Cell Carcinoma
- Neck Dissection
- Elective neck dissection
- Therapeutic neck dissection
- (no location specified)
Apr 10, 2023
B-Cell Non-Hodgkin Lymphoma Trial in Seattle (Anakinra)
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- Anakinra
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Cataract Trial in Trieste (ICB00 IOL, ZCB00 IOL, CNA0T0 IOL)
Completed
- Cataract
- ICB00 IOL
- +2 more
-
Trieste, Friuli Venezia Giulia, ItalyUniversity Eye Clinic of Trieste
Oct 31, 2023
Larynx Cancer Stage I, Glottic Carcinoma Trial in Cairo (Hypofractionated single vocal cord irradiation, Whole laryngeal
Recruiting
- Larynx Cancer Stage I
- Glottic Carcinoma
- Hypofractionated single vocal cord irradiation
- Whole laryngeal radiotherapy
-
Cairo, EgyptNational Cancer Institute, Cairo University
Jan 10, 2023
Lung Graft Dysfunction Trial (Blood collection T0, Blood collection 6 months)
Not yet recruiting
- Lung Graft Dysfunction
- Blood collection T0
- Blood collection 6 months
- (no location specified)
Oct 27, 2023
Acute Myeloid Leukemia Trial in Beijing (CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg,1.0 x 10^6 CAR-T+ cells/kg))
Recruiting
- Acute Myeloid Leukemia
- CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg,1.0 x 10^6 CAR-T+ cells/kg)
-
Beijing, Beijing, ChinaBeijing Gaobo Boren Hospital
Feb 23, 2022